argenx SE

argenx SE

ARGNF - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$55.24B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
argenx SEargenx SE45.5-29%9.2-

Earnings Call Q3 2026

October 22, 2026 - AI Summary

Strong financial performance; capacity to invest - Q3’26 product net sales: $1.7B, +54% YoY and +13% QoQ; U.S. $1.5B (U.S. +16% QoQ). - Gross-to-net: 22% (in line with expectations). - Operating profit: $486M, 28% operating margin (or 37% excluding $150M Forte transaction cost). - Cash: $3.7B after paying a net $2.1B for the Forte acquisition. - Full-year 2026 OpEx guidance raised/updated to ~ $4B (combined R&D + SG&A), reflecting Forte-related costs (~+half of the increase), FB102 investment, and ramping commercial/infrastructure after ALKIVIA.
2026–2027 outlook: multiple potential launches; Vision 2030 on track - Company reiterates confidence in Vision 2030: 50,000 patients by end of decade, with the bulk from MG and CIDP; IMNM and possibly MMN are incremental. - 2027 could include up to 5 U.S. launches across the portfolio (including pediatric MG, ocular MG, VYVGART Hytrulo auto-injector, and potentially MMN if December data is positive), plus additional clinical/label expansion. - They expect 5 potential launches in 2027 as “significant progress” toward Vision 2030 and long-term growth.
VYVGART (e.g., efgartigimod) momentum + label expansion catalysts (MG/CIDP) - MG: Momentum continues ~5 years post-launch; seronegative gMG launch driving growth (started with coverage for ~96% of covered lives; payers remove serotype testing hurdles for many). - Halo effect: ~10% of seronegative prescribers are new to VYVGART, and physicians report increased prescribing into seropositive disease too. - Pediatric MG and ocular MG: Supplemental BLA submitted for both; pediatric PDUFA Feb 2027, ocular MG could extend beyond generalized MG for the first time. - CIDP: steady adoption continues; more prescribers/patients gaining experience; prefilled syringe improves convenience and supports uptake. - Opportunity framing: real-world MG data (MGFA cohort cited) suggests patients starting VYVGART within a year of diagnosis have a higher likelihood of reaching minimal symptom expression.

Exclusive for Stockcircle Pro members

Sign upSign Up

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$55.24 Billion
Enterprise Value$51.75 Billion
Earnings per Share$21.94
Beta-0.02
Outstanding Shares62,735,385

Return

Return on Equity29.29%ROE
Return on Assets24.57%
Return on Invested Capital28.97%

Valuation & Multiples

P/E Ratio45.52P/E Ratio
PEG42.85PEG
Price to Sales9.19Price to Sales
Price to Book Ratio7.2Price to Book Ratio
Enterprise Value to Revenue7.85
Enterprise Value to EBIT21.13
Enterprise Value to Net Income20
Total Debt to Enterprise0
Debt to Equity0.01Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
October 22, 2026
EPS
$13.19
Est. $7.02
Revenue
$2.75 B
Est. $1.47 B

Next Earnings Call

Expected Date
February 25, 2027
EPS Estimate
-
Consensus analyst estimate
Revenue Estimate
$3.16 B
Consensus analyst estimate

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

About Argen X SE

1,599 employees
CEO: Tim Van Hauwermeiren

argenx SE is a biotechnology firm dedicated to advancing innovative treatments for autoimmune conditions across key global markets, including the United States, several European nations (the Netherlands, Belgium, Switzerland, Germany, Fr...